Fennec Pharmaceuticals Stock (NASDAQ:FENC)
Previous Close
$5.39
52W Range
$5.00 - $11.92
50D Avg
$5.92
200D Avg
$8.40
Market Cap
$149.68M
Avg Vol (3M)
$94.79K
Beta
0.26
Div Yield
-
FENC Company Profile
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
FENC Performance
Peer Comparison
| Ticker | Company |
|---|---|
| OLMA | Olema Pharmaceuticals, Inc. |
| CYT | Cyteir Therapeutics, Inc. |
| DBTX | Decibel Therapeutics, Inc. |
| IKNA | Ikena Oncology, Inc. |
| LRMR | Larimar Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| OBIO | Orchestra BioMed Holdings, Inc. |
| IRON | Disc Medicine, Inc. |
| CSBR | Champions Oncology, Inc. |
| JANX | Janux Therapeutics, Inc. |
| KROS | Keros Therapeutics, Inc. |
| HRMY | Harmony Biosciences Holdings, Inc. |
| MNOV | MediciNova, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| MOLN | Molecular Partners AG |
| ELYM | Eliem Therapeutics, Inc. |